Skin lesions in chronic myeloid leukemia patients during dasatinib treatment

PURPOSE: In our work we sought to define the prevalence rates of cutaneous events during dasatinib therapy in chronic myeloid leukemia (CML) patients and to investigate the clinical and pathological characteristics of these reactions. PATIENTS AND METHODS: In our institution, 67 CML patients were tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Tarantini, Francesco, Anelli, Luisa, Ingravallo, Giuseppe, Attolico, Immacolata, Zagaria, Antonella, Russo Rossi, Antonella, Lospalluti, Lucia, Bufano, Tamara, Zanframundo, Giovanni, Maiorano, Eugenio, Specchia, Giorgina, Albano, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717053/
https://www.ncbi.nlm.nih.gov/pubmed/31692557
http://dx.doi.org/10.2147/CMAR.S217872

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717053/
https://www.ncbi.nlm.nih.gov/pubmed/31692557
http://dx.doi.org/10.2147/CMAR.S217872

Ejemplares similares